Related references
Note: Only part of the references are listed.Prostate cancer screening: current status and future perspectives
Seth A. Strope et al.
NATURE REVIEWS UROLOGY (2010)
ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification
B. Furusato et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2010)
Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing
Rebecca J. Leary et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer
Kyung Park et al.
NEOPLASIA (2010)
TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis
Kari Rostad et al.
APMIS (2009)
Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer
Nicolas B. Delongchamps et al.
BJU INTERNATIONAL (2009)
Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer
J. Nilsson et al.
BRITISH JOURNAL OF CANCER (2009)
Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States
Juan-Miguel Mosquera et al.
CLINICAL CANCER RESEARCH (2009)
Screening for Prostate Cancer in 2008 II: The Importance of Molecular Subforms of Prostate-Specific Antigen and Tissue Kallikreins
Flip H. Jansen et al.
EUROPEAN UROLOGY (2009)
ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice
Scott A. Tomlins et al.
EUROPEAN UROLOGY (2009)
Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context
Gerrit Draisma et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression
Bo Han et al.
MODERN PATHOLOGY (2009)
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
Jennifer C. King et al.
NATURE GENETICS (2009)
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Brett S. Carver et al.
NATURE GENETICS (2009)
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Gerald L. Andriole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schroeder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells
Yang Zong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial
Robert L. Grubb et al.
BJU INTERNATIONAL (2008)
An Updated Catalog of Prostate Cancer Predictive Tools
Shahrokh F. Shariat et al.
CANCER (2008)
Use of the prostate-specific antigen test among US men: Findings from the 2005 national health interview survey
Louie E. Ross et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention
M. Scott Lucia et al.
CANCER PREVENTION RESEARCH (2008)
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer
Bharathi Laxman et al.
CANCER RESEARCH (2008)
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications
Juan-Miguel Mosquera et al.
CLINICAL CANCER RESEARCH (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prostate cancer volume at biopsy predicts clinically significant upgrading
Fei Dong et al.
JOURNAL OF UROLOGY (2008)
PCA3: A molecular urine assay for predicting prostate biopsy outcome
Ina L. Deras et al.
JOURNAL OF UROLOGY (2008)
Needle biopsies on autopsy prostates: Sensitivity of cancer detection based on true prevalence
Gabriel P. Haas et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer
Daphne Hessels et al.
CLINICAL CANCER RESEARCH (2007)
Development and external validation of an extended 10-core biopsy nomogram
Felix K. -H. Chun et al.
EUROPEAN UROLOGY (2007)
Decision curve analysis: A novel method for evaluating prediction models
Andrew J. Vickers et al.
MEDICAL DECISION MAKING (2006)
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer
Bharathi Laxman et al.
NEOPLASIA (2006)
APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer
Jack Groskopf et al.
CLINICAL CHEMISTRY (2006)
Assessing prostate cancer risk: Results from the prostate cancer prevention trial
IM Thompson et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Use of extended pattern technique for initial prostate biopsy
W Siu et al.
JOURNAL OF UROLOGY (2005)
Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels:: aggressive or insignificant?
C Gosselaar et al.
BJU INTERNATIONAL (2005)
Characteristics of insignificant clinical T1c prostate tumors - A contemporary analysis
PJ Bastian et al.
CANCER (2004)
Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter
IM Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
